IntelGenx Technologies (IGXT) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 25, 2016	Jun. 30, 2015
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Trading Symbol	igxt
Entity Registrant Name	IntelGenx Technologies Corp.
Entity Central Index Key	1,098,880
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		63,615,256
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Public Float			$ 35,540,543
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current
Cash and cash equivalents	$ 2,865	$ 4,399
Accounts receivable	1,140	652
Prepaid expenses	70	96
Investment tax credits receivable	97	108
Total Current Assets	4,172	5,255
Leasehold Improvements and Equipment, net	4,238	983
Intangible Assets	0	46
Security Deposits	506	0
Total Assets	8,916	6,284
Current
Accounts payable and accrued liabilities	1,595	466
Current portion of long-term debt	184	0
Deferred license revenue	0	1,245
Total Current Liabilities	1,779	1,711
Deferred lease obligations	27	0
Long-term debt	1,546	0
Total Liabilities	3,352	1,711
Shareholders' Equity
Capital Stock, common shares, $0.00001 par value; 100,000,000 shares authorized; 63,615,255 shares issued and outstanding (December 31, 2014; 63,465,255 common shares)	1	1
Additional Paid-in-Capital	22,846	22,654
Accumulated Deficit	(16,557)	(17,848)
Accumulated Other Comprehensive Loss	(726)	(234)
Total Shareholders' Equity	5,564	4,573
Total Liabilities and Shareholders' Equity	$ 8,916	$ 6,284

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Common Stock, Par Value Per Share	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	63,615,255	63,465,255
Common Stock, Shares, Outstanding	63,615,255	63,465,255

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity - USD ($) $ in Thousands	Capital Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning Balance at Dec. 31, 2013	$ 1	$ 20,934	$ (16,102)	$ 175	$ 5,008
Beginning Balance (Shares) at Dec. 31, 2013	60,984,267
Foreign currency translation adjustment				(409)	(409)
Warrants exercised		1,619			1,619
Warrants exercised (Shares)	2,480,988
Stock-based compensation		101			101
Net loss for the year			(1,746)		(1,746)
Ending Balance at Dec. 31, 2014	$ 1	22,654	(17,848)	(234)	4,573
Ending Balance (Shares) at Dec. 31, 2014	63,465,255
Foreign currency translation adjustment				(492)	(492)
Options exercised		62			62
Options exercised (Shares)	150,000
Stock-based compensation		130			130
Net loss for the year			1,291		1,291
Ending Balance at Dec. 31, 2015	$ 1	$ 22,846	$ (16,557)	$ (726)	$ 5,564
Ending Balance (Shares) at Dec. 31, 2015	63,615,255

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues
Royalties	$ 981	$ 476
License and other revenue	4,114	1,183
Total Revenues	5,095	1,659
Expenses
Cost of royalty and license revenue	433	61
Research and development expense	1,033	1,075
Selling, general and administrative expense	2,072	2,229
Depreciation of tangible assets	125	35
Amortization of intangible assets	46	39
Total Expenses	3,709	3,439
Operating Income (Loss)	1,386	(1,780)
Interest Income	28	34
Financing and Interest expense	(123)	0
Total Other Income	(95)	34
Income (Loss) Before Income Taxes	1,291	(1,746)
Income taxes	0	0
Net Income (Loss)	1,291	(1,746)
Other Comprehensive Income (Loss)
Foreign currency translation adjustment	(492)	(409)
Comprehensive Income (Loss)	$ 799	$ (2,155)
Basic: Weighted Average Number of Shares Outstanding	63,524,023	63,182,224
Basic Earnings (Loss) Per Common Share	$ 0.01	$ (0.03)
Diluted: Weighted Average Number of Shares Outstanding	70,855,146	63,182,224
Diluted Earnings (Loss) Per Common Share	$ 0.01	$ (0.03)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Funds Provided (Used) - Operating Activities
Net Income (Loss)	$ 1,291	$ (1,746)
Amortization and depreciation	171	74
Stock-based compensation	130	101
Total Adjustments	1,592	(1,571)
Changes in assets and liabilities
Accounts receivable	(488)	(508)
Prepaid expenses	26	37
Investment tax credits receivable	11	160
Security deposits	(506)	0
Accounts payable and accrued liabilities	1,129	(127)
Deferred revenue	(1,245)	629
Deferred lease obligations	27	0
Net change in assets and liabilities	(1,046)	191
Net cash provided (used) by operating activities	546	(1,380)
Financing Activities
Issuance of term loans	1,752	0
Repayment of term loans	(22)	0
Proceeds from exercise of warrants and stock options	62	1,619
Net cash provided by financing activities	1,792	1,619
Investing Activities
Additions to leasehold improvements and equipment	(3,380)	(403)
Net cash used in investing activities	(3,380)	(403)
Decrease in Cash and Cash Equivalents	(1,042)	(164)
Effect of Foreign Exchange on Cash and Cash Equivalents	(492)	(442)
Cash and Cash Equivalents
Beginning of Year	4,399	5,005
End of Year	$ 2,865	$ 4,399

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Basis of Presentation [Text Block]	1. Basis of Presentation IntelGenx Technologies Corp. (“IntelGenx” or the “Company”) prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“USA”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated. The financial statements are expressed in U.S. funds.

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2015
Nature of Business [Text Block]	2. Nature of Business IntelGenx was incorporated in the State of Delaware as Big Flash Corp. on July 27, 1999. On April 28, 2006 Big Flash Corp. completed, through the Canadian holding corporation, the acquisition of IntelGenx Corp., a company incorporated in Canada on June 15, 2003. IntelGenx is a pharmaceutical company focused on the research, development, and commercialization of pharmaceutical products based upon three proprietary delivery platforms, including an immediate release oral film “VersaFilm™”, a mucoadhesive tablet “AdVersa™”, and a multilayer controlled release tablet “VersaTab™”. The Company has an aggressive product development initiative that primarily focuses on addressing unmet market needs and focuses on utilization of the U.S. Food and Drug Administration’s (“FDA”) 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved products. The Company’s product pipeline currently consists of 10 products in various stages of development from inception through commercialization, including products for the treatment of major depressive disorder, opioid dependence, hypertension, erectile dysfunction, migraine, schizophrenia, idiopathic pulmonary fibrosis, and pain management. Of the products currently under development, 6 utilize the VersaFilm™ VersaTab™ AdVersa™ The Company’s first FDA-approved product, Forfivo XL®, was launched in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP. Forfivo XL® is indicated for the treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL® is bupropion, the same active ingredient used in Wellbutrin XL®.

Adoption of New Accounting Stan

Adoption of New Accounting Standards	12 Months Ended
	Dec. 31, 2015
Adoption of New Accounting Standards [Text Block]	3. Adoption of New Accounting Standards The FASB issued ASU No. 2014-08 which enhances convergence between U.S. GAAP and International Financial Reporting Standards (IFRS). The amendments in the ASU change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expands disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in the ASU were effective in the first quarter of 2015 for public organizations with calendar year ends. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Summary of Significant Accounting Policies [Text Block]	4. Summary of Significant Accounting Policies Revenue Recognition The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, recorded as other revenue, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income. IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured. For the year ended December 31, 2015, the Company recognized royalty revenue earned under a licensing agreement totaling $946 thousand compared to $463 thousand in 2014. For the year ended December 31, 2015, the Company recognized revenues as a result of sales milestones achieved under a licensing agreement totaling $2,808 thousand (2014: $Nil). For the year ended December 31, 2015, the Company recognized revenues as a result of sales milestones achieved under a development and commercialization agreement in the amount of $Nil (2014: $552). Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants. Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions. Cash and Cash Equivalents Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value. Accounts Receivable The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2015 accounts receivable (2014: $Nil). Investment Tax Credits Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. Investment tax credits received in the year ended December 31, 2015 totaled $108 thousand (2014: $268 thousand). Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 – 10 years Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. Intangible Assets Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. Security Deposits Security deposits represent a refundable deposit paid to the landlord in accordance with the lease agreement and deposits held as guarantees by the Company’s lenders in accordance with the lending facilities. Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof. Deferred Lease Obligations Rent under operating leases is charged to expense on a straight-line basis over the lease term. Any difference between the rent expense and the rent payable is reflected as deferred lease obligations on the balance sheet. Deferred lease obligations are amortized on a straight-line basis over the term of the related leases. Lease term includes free rent periods as well as the construction period prior to the commencement of the lease. Foreign Currency Translation The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: Assets and liabilities - at exchange rates in effect at the balance sheet date; Fixed assets - at historical rates Revenue and expenses - at average exchange rates prevailing during the year; Equity - at historical rates. Gains and losses arising from foreign currency translation are included in other comprehensive income. Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision. Share-Based Payments The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year. Earnings (Loss) Per Share Basic earnings (loss) per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted earnings (loss) per share. Fair Value Measurements ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2015. Fair Value of Financial Instruments The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization. Recent Accounting Pronouncements ASU 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments The FASB issued this Update which requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments in this Update require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments in this Update require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The amendments in this Update apply to all entities that have reported provisional amounts for items in a business combination for which the accounting is incomplete by the end of the reporting period in which the combination occurs and during the measurement period have an adjustment to provisional amounts recognized. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments in this Update should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this Update with earlier application permitted for financial statements that have not yet been issued. For all other entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December 15, 2017. The adoption of this Statement is not expected to have a material effect on the Company`s financial position or results of operations. ASU 2015-14, Revenue From Contracts With Customers (Topic 606), Deferral of the Effective Date The FASB and IASB (the Boards) have issued converged standards on revenue recognition. ASU No. 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: • Step 1: Identify the contract(s) with a customer. • Step 2: Identify the performance obligations in the contract. • Step 3: Determine the transaction price. • Step 4: Allocate the transaction price to the performance obligations in the contract. • Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in Update 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. All other entities should apply the guidance in Update 2014-09 to annual reporting periods beginning after December 15, 2018, and interim reporting periods within annual reporting periods beginning after December 15, 2019. All other entities may apply the guidance in Update 2014-09 earlier as of an annual reporting period beginning after December 15, 2016, including interim reporting periods within that reporting period. All other entities also may apply the guidance in Update 2014-09 earlier as of an annual reporting period beginning after December 15, 2016, and interim reporting periods within annual reporting periods beginning one year after the annual reporting period in which the entity first applies the guidance in Update 2014-09. This ASU is to be applied retrospectively, with certain practical expedients allowed. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory The amendments in this Update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards (IFRS). An entity should measure inventory within the scope of this Update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The Board has amended some of the other guidance in Topic 330 to more clearly articulate the requirements for the measurement and disclosure of inventory. However, the Board does not intend for those clarifications to result in any changes in practice. Other than the change in the subsequent measurement guidance from the lower of cost or market to the lower of cost and net realizable value for inventory within the scope of this Update, there are no other substantive changes to the guidance on measurement of inventory. The amendments in this Update do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. For all other entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December 15, 2017. The amendments in this Update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of this Statement is not expected to have a material effect on the Company`s financial position or results of operations. ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs The amendments in ASU 2015-03 are intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for public business entities for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted for financial statements that have not been previously issued. The adoption of this Statement is not expected to have a material effect on the Company`s financial position or results of operations. ASU 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items The amendments in ASU 2015-01 eliminate from U.S. GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. The FASB heard from stakeholders that the concept of extraordinary items causes uncertainty because it is unclear when an item should be considered both unusual and infrequent. Additionally, some stakeholders said that although users find information about unusual or infrequent events and transactions useful, they do not find the extraordinary item classification and presentation necessary to identify those events and transactions. Other stakeholders noted that it is extremely rare in current practice for a transaction or event to meet the requirements to be presented as an extraordinary item. This ASU will also align more closely U.S. GAAP income statement presentation guidance with IAS 1, Presentation of Financial Statements, ASU 2014-15, Presentation of Financial Statements —Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern The FASB has issued ASU No. 2014-15 which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. This ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The amendments are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for shared-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The FASB has issued ASU No. 2014-12 which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation – Stock Compensation, ASU 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In January 2016, the FASB issued ASU 2016-01, which will significantly change practice for all entities. The targeted amendments to existing guidance are expected to include: 1. Equity investments that do not result in consolidation and are not accounted for under the equity method would be measured at fair value through net income, unless they qualify for the proposed practicability exception for investments that do not have readily determinable fair values. 2. Changes in instrument-specific credit risk for financial liabilities that are measured under the fair value option would be recognized in other comprehensive income. 3. Entities would make the assessment of the realizability of a deferred tax asset (DTA) related to an available- for-sale (AFS) debt security in combination with the entity’s other DTAs. The guidance would eliminate one method that is currently acceptable for assessing the realizability of DTAs related to AFS debt securities. That is, an entity would no longer be able to consider its intent and ability to hold debt securities with unrealized losses until recovery. 4. Disclosure of the fair value of financial instruments measured at amortized cost would no longer be required for entities that not public business entities. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. For all other entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Entities would be able to early adopt a provision that would allow them to recognize the fair value change from own credit in other comprehensive income for financial liabilities measured under the fair value option, and entities that are not public business entities would be able to adopt a provision to eliminate the fair value disclosures for financial instruments not recognized at fair value. Non-public business entities would be able to early adopt the guidance as of the effective date for public business entities. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”) In November 2015, the FASB issued ASU 2015-17, which require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments. For all other entities, the amendments are effective for financial statements issued for annual periods beginning after December 15, 2017, and interim periods within annual periods beginning after December 15, 2018. The Company is currently evaluating the impact of its pending adoption of ASU 2015-17 on its financial statements.

Leasehold Improvements and Equi

Leasehold Improvements and Equipment	12 Months Ended
	Dec. 31, 2015
Leasehold Improvements and Equipment [Text Block]	5. Leasehold improvements and Equipment 2015 2014 Accumulated Net Carrying Net Carrying In U.S. $ thousands Cost Depreciation Amount Amount Manufacturing equipment $ 1,050 $ 0 $ 1,050 $ 520 Laboratory and office equipment 1,193 372 821 241 Computer equipment 64 47 17 15 Leasehold improvements 2,427 77 2,350 207 $ 4,734 $ 496 $ 4,238 $ 983 As of December 31, 2015 no depreciation has been recorded on manufacturing equipment as this equipment is not yet in use. As of December 31, 2015 no depreciation has been recorded on laboratory equipment in the amount of $471 as the equipment is not yet in use.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2015
Intangible Assets [Text Block]	6. Intangible Assets As of December 31, 2015 NDA acquisition costs representing the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL® were fully amortized.

Deferred License Revenue

Deferred License Revenue	12 Months Ended
	Dec. 31, 2015
Deferred License Revenue [Text Block]	7. Deferred License Revenue Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur. Pursuant to the execution of a licensing agreement for Forfivo XL®, IntelGenx received an upfront fee from Edgemont Pharmaceuticals (“Edgemont”) in the first quarter of 2012, which IntelGenx recognized as deferred license revenue. The deferred license revenue was amortized in income over a period of 39 months, which was the minimum period where sales of Forfivo XL® are expected to be exclusive. In the fourth quarter of 2014, Edgemont exercised its right to extend the license for the exclusive marketing of Forfivo XL®. In accordance with the terms for exercising such right, IntelGenx invoiced $1.25 million to Edgemont and recognized the full amount as deferred revenue, which was recognized as revenue from October 2014 through September 2015. As of December 31, 2015, the entire deferred revenue balance has been recognized as revenue (December 31, 2014 - $1.24 million that had not been recognized as revenue).

Bank indebtedness

Bank indebtedness	12 Months Ended
	Dec. 31, 2015
Bank indebtedness [Text Block]	8. Bank Indebtedness The Company's credit facility is subject to review annually and consists of an operating demand line of credit of up to CAD$250 thousand and corporate credits cards of up to CAD$55 thousand. Borrowings under the operating demand line of credit bear interest at the Bank’s prime lending rate plus 2%. The credit facility and term loan (see note 9) are secured by a first ranking movable hypothec on all present and future movable property of the Company and a 50% guarantee by Export Development Canada, a Canadian Crown corporation export credit agency. The terms of the banking agreement require the Company to comply with certain debt service coverage and debt to net worth financial covenants on an annual basis at the end of the Company’s fiscal year. As at December 31, 2015, the Company was in compliance with its financial covenants and has not drawn on its credit facility.

Long-term debt

Long-term debt	12 Months Ended
	Dec. 31, 2015
Long-term debt [Text Block]	9. Long-term debt The components of the Company’s debt are as follows: December 31, 2015 December 31, 2014 In U.S.$ thousands $ $ Term loan facility 1,188 - Secured loan 542 - Total debt 1,730 - Less: current portion 184 - Total long-term debt 1,546 - The Company’s term loan facility consists of a total of CAD$3.5 million, consisting of CAD$1.6 million bearing interest at the Bank’s prime lending rate plus 2.50%, and CAD$1.8 million bearing interest at a fixed rate to be determined at drawdown. The term loan is subject to the same security and financial covenants as the bank indebtedness (see note 8). The CAD$1.8 million tranche of the term loan will be disbursed subsequent to meeting certain conditions. There is a moratorium on capital repayments for the first 6 months of each drawdown, at which point the term loan will be repayable in monthly instalments over 60 months. The secured loan has a principal balance authorized of CAD$1 million of which CAD$0.75 million was disbursed as at December 2015, bearing interest at prime plus 7.3%, reimbursable in monthly principal payments of CAD$12,5 thousand from January 2017 to December 2021. The loan is secured by a second ranking on all present and future property of the Company. The terms of the banking agreement require the Company to comply with certain debt service coverage and debt to net worth financial covenants on an annual basis at the end of the Company’s fiscal year. As at December 31, 2015, the Company was in compliance with its financial covenants. Principal repayments due in each of the next five years are as follows: In U.S.$ thousands 2016 $184 2017 344 2018 344 2019 344 2020 344 Thereafter 170

Commitments

Commitments	12 Months Ended
	Dec. 31, 2015
Commitments [Text Block]	10. Commitments On April 24, 2015 the Company entered into an agreement to lease approximately 17,000 square feet in a property located at 6420 Abrams, St-Laurent, Québec. The Lease has a 10 year and 6 -month term commencing September 1, 2015. IntelGenx has retained two options to extend the lease, with each option being for an additional five years. Under the terms of the lease IntelGenx is required to pay base rent of approximately CAD$110 thousand (approximately $80 thousand) per year, which will increase at a rate of CAD$0.25 ($0.18) per square foot every two years. IntelGenx is using the newly leased space for manufacturing its oral film VersaFilm™ products, enlarging research and development capabilities, and for administration. The aggregate minimum rentals, exclusive of other occupancy charges, for property leases expiring in 2026, are approximately $866 thousand, as follows: In U.S.$ thousands 2016 $66 2017 81 2018 83 2019 84 2020 86 Thereafter 466 On March 3, 2015, the Company signed an agreement in the amount of Euro1,490 thousand with a supplier with respect to the fabrication of customized manufacturing equipment. As at December 31, 2015, an amount of Euro298 thousand had been paid. On May 7, 2010, the Company executed a Project Transfer Agreement with one of its former development partners whereby the Company acquired full rights to, and ownership of, Forfivo XL®, a novel, high strength formulation of Bupropion hydrochloride, the active ingredient in Wellbutrin XL®. In accordance with the Project Transfer Agreement, and following commercial launch of Forfivo XL® in October 2012, the Company is required, after recovering an aggregate $200 thousand for management fees previously paid, to pay its former development partner 10% of net income received from the sale of Forfivo XL®. In December 2014 the Company fully recovered said management fees and owed approximately $58 thousand to its former development partner that was remitted in February 2015. During fiscal year 2015 the amount due was $433.

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2015
Capital Stock [Text Block]	11. Capital Stock 2015 2014 Authorized - 100,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 63,615,255 (December 31, 2014: 63,465,255) common shares $ 636 $ 635 Stock options During the year ended December 31, 2015 a total of 150,000 stock options were exercised for 150,000 common shares having a par value of $0 thousand in aggregate, for cash consideration of $62 thousand, resulting in an increase in additional paid-in capital of $62 thousand. No stock options were exercised in the year ended December 31, 2014. Stock-based compensation of $130 thousand and $101 thousand was recorded during the year ended December 31, 2015 and 2014 respectively. The entire amounts expensed in 2015 and 2014 relate to stock options granted to employees and directors. As at December 31, 2015 the Company has $158 thousand (2014 - $74 thousand) of unrecognized stock-based compensation. Warrants No warrants were exercised during the year ended December 31, 2015. In the year ended December 31, 2014 a total of 2,480,988 warrants were exercised for 2,480,988 common shares having a par value of $Nil in aggregate, for cash consideration of approximately $1,619 thousand, resulting in an increase in additional paid-in capital of approximately $1,619 thousand.

Additional Paid-In Capital

Additional Paid-In Capital	12 Months Ended
	Dec. 31, 2015
Additional Paid-In Capital [Text Block]	12. Additional Paid-In Capital Stock Options In November 2006, the Company adopted the 2006 Stock Incentive Plan (the "Plan") for the purpose of issuing both Incentive Options and Nonqualified Options to officers, employees, directors and eligible consultants of the Company. A total of 1,600,749 shares of common stock were reserved for issuance under this plan. Options may be granted under the Plan on terms and at prices as determined by the Board of Directors except that the options cannot be granted at less than 100%, of the fair market value of the common stock on the date of the grant. Each option will be exercisable after the period or periods specified in the option agreement, but no option may be exercised after the expiration of 10 years from the date of grant. All options granted to individuals other than non- employee directors will have a total vesting period of 24 months from the date of grant, with one quarter of the total options granted vesting and becoming exercisable every six months. Options granted to non-employees may vest and become 100% fully exercisable immediately upon grant. In the second quarter of 2008, the life of the options was reduced from 10 years to 5 years to comply with the regulations of the Toronto Stock Exchange. Accordingly, because the grant-date fair value of the modified options was less than the fair value of the original options measured immediately before the modification, no incremental share-based compensation expense resulted from the modification. At the Annual General Meeting (“AGM”) on September 8, 2008 the shareholders of the Company approved an amendment to increase the number of shares available for issuance under the Plan from 1,600,749 to 2,074,000, or 10% of the Company’s issued and outstanding common shares as of July 28, 2008. Subsequent amendments were approved by the shareholders at the AGM’s held on June 3, 2010 and on May 7, 2013 to increase the number of shares available for issuance to 3,308,127 and 5,030,292 respectively. On December 8, 2014 the Company granted an aggregate of 175,000 options purchase common stock to three non-employee directors, two officers, and two employees. The stock options are exercisable at $0.53 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $36 thousand, using the following assumptions: Expected volatility 63% Expected life 3.13 years Risk-free interest rate 1.10% Dividend yield nil On April 2, 2015 the Company granted 200,000 options to purchase common stock to four non-employee directors. The stock options are exercisable at $0.62, and vested immediately. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $45 thousand, using the following assumptions: Expected volatility 66% Expected life 2.5 years Risk-free interest rate 0.87% Dividend yield nil On April 2, 2015 the Company granted 100,000 options to purchase common stock to an officer. The stock options are exercisable at $0.62 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $24 thousand, using the following assumptions: Expected volatility 62% Expected life 3.13 years Risk-free interest rate 0.87% Dividend yield nil On July 20, 2015 the Company granted 600,000 options to purchase common stock to an employee. The stock options are exercisable at $0.58 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $120 thousand, using the following assumptions: Expected volatility 63% Expected life 3.13 years Risk-free interest rate 1.09% Dividend yield nil On August 13, 2015 the Company granted 75,000 options to purchase common stock to a non-employee director. The stock options are exercisable at $0.58 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $15 thousand, using the following assumptions: Expected volatility 62% Expected life 3.13 years Risk-free interest rate 1.06% Dividend yield nil On December 14, 2015 the Company granted 150,000 options to purchase common stock to an employee. The stock options are exercisable at $0.48 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $25 thousand, using the following assumptions: Expected volatility 63% Expected life 3.13 years Risk-free interest rate 1.25% Dividend yield nil During the year ended December 31, 2015 a total of 150,000 options were exercised for 150,000 common stock having a par value of $0 thousand in aggregate, for cash consideration of $62 thousand, resulting in an increase in additional paid-in capital of $62 thousand. The intrinsic value of the stock options exercised, as at the dates of exercise, totaled $31 thousand. No stock options were exercised in the year ended December 31, 2014. Information with respect to employees and directors stock option activity for 2014 and 2015 is as follows: Weighted average Number of options exercise price $ Outstanding – January 1, 2014 1,597,500 0.58 Granted 175,000 0.53 Forfeited (517,500 ) (0.64 ) Expired (125,000 ) (0.61 ) Exercised - - Outstanding – December 31, 2014 1,130,000 0.54 Granted 1,125,000 0.58 Forfeited (410,000 ) (0.59 ) Expired (25,000 ) (0.45 ) Exercised (150,000 ) (0.41 ) Outstanding – December 31, 2015 1,670,000 0.56 Information with respect to consultant’s stock option activity for 2014 and 2015 is as follows: Weighted average Number of options exercise price $ Outstanding – January 1, 2014 and 2015 100,000 0.59 Expired (100,000 ) 0.59 Outstanding – December 31, 2015 - - Details of stock options outstanding as at December 31, 2015 are as follows: Outstanding options Exercisable options Weighted Weighted Weighted average average Aggregate average Aggregate Exercise Number of remaining exercise intrinsic Number of exercise intrinsic prices options contractual life price value options price value $ (years) $ $ $ $ 0.48 150,000 0.45 0.04 - - 0.51 20,000 0.02 0.01 20,000 0.01 0.52 50,000 0.01 0.02 50,000 0.04 0.52 150,000 0.27 0.05 150,000 0.11 0.53 150,000 0.36 0.05 75,000 0.06 0.54 110,000 0.06 0.04 110,000 0.09 0.58 35,000 0.06 0.01 35,000 0.03 0.58 600,000 1.65 0.21 - - 0.58 75,000 0.21 0.03 - - 0.60 30,000 0.04 0.01 30,000 0.03 0.62 300,000 0.76 0.11 225,000 0.20 1,670,000 3.88 0.56 6,200 695,000 0.56 200 Stock-based compensation expense recognized in 2015 with regards to the stock options was $130 thousand (2014: $101 thousand). As of December 31, 2015, total unrecognized compensation expense related to unvested stock options was $158 thousand (2014: $74 thousand), all of which relates to options granted to employees and directors. The amount of $158 thousand will be recognized as an expense over a period of two years. A change in control of the Company due to acquisition would cause the vesting of the stock options granted to employees and directors to accelerate and would result in $158 thousand being charged to stock based compensation expense. Warrants No warrants were exercised in the year ended December 31, 2015. In the year ended December 31, 2014 a total of 2,480,988 warrants were exercised for 2,480,988 common shares having a par value of $Nil in aggregate, for cash consideration of approximately $1,619 thousand, resulting in an increase in additional paid-in capital of approximately $1,619 thousand. Information with respect to warrant activity for 2014 and 2015 is as follows: Number of Weighted average warrants exercise price (All Exercisable) $ Outstanding – January 1, 2014 11,143,732 0.6079 Exercised (2,480,988 ) (0.6524 ) Expired (1,431,621 ) (0.7400 ) Outstanding - December 31, 2014 7,231,123 0.5646 Exercised - - Expired - - Outstanding - December 31, 2015 7,231,123 0.5646

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2015
Income Tax [Text Block]	13. Income Taxes Income taxes reported differ from the amount computed by applying the statutory rates to net income (losses). The reasons are as follows: In U.S.$ thousands 2015 2014 Statutory income taxes $ 387 $ (429 ) Net operating losses for which no tax benefits have been recorded - 238 Net operating losses used for which no tax benefit had been recorded (484 ) - Excess (deficiency) of depreciation over capital cost allowance (98 ) 9 Non-deductible expenses 44 26 Undeducted research and development expenses 178 181 Investment tax credit (27 ) (25 ) $ - $ - The major components of the deferred tax assets classified by the source of temporary differences are as follows: In U.S.$ thousands 2015 2014 Leasehold improvements and equipment $ 117 $ 9 Net operating losses carryforward 1,770 2,582 Undeducted research and development expenses 1,274 1,355 Non-refundable tax credits carryforward 1,022 1,102 4,183 5,048 Valuation allowance (4,183 ) (5,048 ) $ - $ - As at December 31, 2015, management determined that enough uncertainty existed relative to the realization of deferred income tax asset balances to warrant the application of a full valuation allowance. Although management believes that certain of the net operating losses will be applied against earnings in 2016, management continues to believe that enough uncertainty exists relative to the realization of the remaining deferred income tax asset balances such that no recognition of deferred income tax assets is warranted. There were Canadian and provincial net operating losses of approximately $6,462 thousand (2014: $9,530 thousand) and $6,725 thousand (2014: $9,683 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2027 and 2035. A portion of the net operating losses may expire before they can be utilized. As at December 31, 2015, the Company had non-refundable tax credits of $1,022 thousand (2014: $1,102 thousand) of which $8 thousand is expiring in 2026, $9 thousand is expiring in 2027, $163 thousand is expiring in 2028, $143 thousand is expiring in 2029, $122 thousand is expiring in 2030, $129 thousand is expiring in 2031, $162 thousand is expiring in 2032 and $108 thousand is expiring in 2033, $82 thousand expiring in 2034 and $96 thousand is expiring in 2035 and undeducted research and development expenses of $6,315 thousand (2014: $4,805 thousand) with no expiration date. The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for. Unrecognized Tax Benefits The Company does not have any unrecognized tax benefits. Tax Years and Examination The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company’s major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2015: Tax Jurisdictions Tax Years Federal - Canada 2012 and onward Provincial - Quebec 2012and onward Federal - USA 2012 onward

Statement of Cash Flows Informa

Statement of Cash Flows Information	12 Months Ended
	Dec. 31, 2015
Statement of Cash Flows Information [Text Block]	14. Statement of Cash Flows Information In US$ thousands 2015 2014 Additional Cash Flow Information: Interest paid $ 23 $ 5

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Text Block]	15. Related party transactions Included in management salaries are $3 thousand (2014: $29 thousand) for options granted to the Chief Executive Officer, $9 thousand (2014: $Nil) for options granted to the Vice President, Operations, and $39 thousand (2014: $43 thousand) for options granted to two Chief Financial Officers under the 2006 Stock Option Plan and $70 thousand (2014: $17 thousand) for options granted to non-employee directors. Included in general and administrative expenses are director fees of $250 thousand (2014: $187 thousand) comprising an annual stipend. The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties.

Basic and Diluted Earnings (Los

Basic and Diluted Earnings (Loss) Per Common Share	12 Months Ended
	Dec. 31, 2015
Basic and Diluted Earnings (Loss) Per Common Share [Text Block]	16. Basic and Diluted Earnings (Loss) Per Common Share Basic and diluted earnings (loss) per common share is calculated based on the weighted average number of shares outstanding during the year. Common equivalent shares from stock options and warrants are also included in the diluted per share calculations unless the effect of the inclusion would be antidilutive.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Revenue Recognition [Policy Text Block]	Revenue Recognition The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, recorded as other revenue, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income. IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured. For the year ended December 31, 2015, the Company recognized royalty revenue earned under a licensing agreement totaling $946 thousand compared to $463 thousand in 2014. For the year ended December 31, 2015, the Company recognized revenues as a result of sales milestones achieved under a licensing agreement totaling $2,808 thousand (2014: $Nil). For the year ended December 31, 2015, the Company recognized revenues as a result of sales milestones achieved under a development and commercialization agreement in the amount of $Nil (2014: $552).
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants. Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.
Cash and Cash Equivalents [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.
Accounts Receivable [Policy Text Block]	Accounts Receivable The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible and records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2015 accounts receivable (2014: $Nil).
Investment Tax Credits [Policy Text Block]	Investment Tax Credits Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. Investment tax credits received in the year ended December 31, 2015 totaled $108 thousand (2014: $268 thousand).
Leasehold Improvements and Equipment [Policy Text Block]	Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 – 10 years Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.
Intangible Assets [Policy Text Block]	Intangible Assets Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
Security Deposits [Policy Text Block]	Security Deposits Security deposits represent a refundable deposit paid to the landlord in accordance with the lease agreement and deposits held as guarantees by the Company’s lenders in accordance with the lending facilities.
Impairment of Long-lived Assets [Policy Text Block]	Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.
Deferred Lease Obligations [Policy Text Block]	Deferred Lease Obligations Rent under operating leases is charged to expense on a straight-line basis over the lease term. Any difference between the rent expense and the rent payable is reflected as deferred lease obligations on the balance sheet. Deferred lease obligations are amortized on a straight-line basis over the term of the related leases. Lease term includes free rent periods as well as the construction period prior to the commencement of the lease.
Foreign Currency Translation [Policy Text Block]	Foreign Currency Translation The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: Assets and liabilities - at exchange rates in effect at the balance sheet date; Fixed assets - at historical rates Revenue and expenses - at average exchange rates prevailing during the year; Equity - at historical rates. Gains and losses arising from foreign currency translation are included in other comprehensive income.
Income Taxes [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Unrecognized Tax Benefits [Policy Text Block]	Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.
Share-Based Payments [Policy Text Block]	Share-Based Payments The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.
Earnings (Loss) Per Share [Policy Text Block]	Earnings (Loss) Per Share Basic earnings (loss) per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted earnings (loss) per share.
Fair Value Measurements [Policy Text Block]	Fair Value Measurements ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2015.
Fair Value of Financial Instruments [Policy Text Block]	Fair Value of Financial Instruments The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.
Recent Accounting Pronouncements [Policy Text Block]	Recent Accounting Pronouncements ASU 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments The FASB issued this Update which requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments in this Update require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments in this Update require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The amendments in this Update apply to all entities that have reported provisional amounts for items in a business combination for which the accounting is incomplete by the end of the reporting period in which the combination occurs and during the measurement period have an adjustment to provisional amounts recognized. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments in this Update should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this Update with earlier application permitted for financial statements that have not yet been issued. For all other entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December 15, 2017. The adoption of this Statement is not expected to have a material effect on the Company`s financial position or results of operations. ASU 2015-14, Revenue From Contracts With Customers (Topic 606), Deferral of the Effective Date The FASB and IASB (the Boards) have issued converged standards on revenue recognition. ASU No. 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. This ASU will supersede the revenue recognition requirements in Topic 605, Revenue Recognition and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: • Step 1: Identify the contract(s) with a customer. • Step 2: Identify the performance obligations in the contract. • Step 3: Determine the transaction price. • Step 4: Allocate the transaction price to the performance obligations in the contract. • Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in Update 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. All other entities should apply the guidance in Update 2014-09 to annual reporting periods beginning after December 15, 2018, and interim reporting periods within annual reporting periods beginning after December 15, 2019. All other entities may apply the guidance in Update 2014-09 earlier as of an annual reporting period beginning after December 15, 2016, including interim reporting periods within that reporting period. All other entities also may apply the guidance in Update 2014-09 earlier as of an annual reporting period beginning after December 15, 2016, and interim reporting periods within annual reporting periods beginning one year after the annual reporting period in which the entity first applies the guidance in Update 2014-09. This ASU is to be applied retrospectively, with certain practical expedients allowed. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory The amendments in this Update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards (IFRS). An entity should measure inventory within the scope of this Update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The Board has amended some of the other guidance in Topic 330 to more clearly articulate the requirements for the measurement and disclosure of inventory. However, the Board does not intend for those clarifications to result in any changes in practice. Other than the change in the subsequent measurement guidance from the lower of cost or market to the lower of cost and net realizable value for inventory within the scope of this Update, there are no other substantive changes to the guidance on measurement of inventory. The amendments in this Update do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. For all other entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2016, and interim periods within fiscal years beginning after December 15, 2017. The amendments in this Update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of this Statement is not expected to have a material effect on the Company`s financial position or results of operations. ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs The amendments in ASU 2015-03 are intended to simplify the presentation of debt issuance costs. These amendments require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for public business entities for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted for financial statements that have not been previously issued. The adoption of this Statement is not expected to have a material effect on the Company`s financial position or results of operations. ASU 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items The amendments in ASU 2015-01 eliminate from U.S. GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement - Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. The FASB heard from stakeholders that the concept of extraordinary items causes uncertainty because it is unclear when an item should be considered both unusual and infrequent. Additionally, some stakeholders said that although users find information about unusual or infrequent events and transactions useful, they do not find the extraordinary item classification and presentation necessary to identify those events and transactions. Other stakeholders noted that it is extremely rare in current practice for a transaction or event to meet the requirements to be presented as an extraordinary item. This ASU will also align more closely U.S. GAAP income statement presentation guidance with IAS 1, Presentation of Financial Statements, ASU 2014-15, Presentation of Financial Statements —Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern The FASB has issued ASU No. 2014-15 which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. This ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The amendments are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for shared-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The FASB has issued ASU No. 2014-12 which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation – Stock Compensation, ASU 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In January 2016, the FASB issued ASU 2016-01, which will significantly change practice for all entities. The targeted amendments to existing guidance are expected to include: 1. Equity investments that do not result in consolidation and are not accounted for under the equity method would be measured at fair value through net income, unless they qualify for the proposed practicability exception for investments that do not have readily determinable fair values. 2. Changes in instrument-specific credit risk for financial liabilities that are measured under the fair value option would be recognized in other comprehensive income. 3. Entities would make the assessment of the realizability of a deferred tax asset (DTA) related to an available- for-sale (AFS) debt security in combination with the entity’s other DTAs. The guidance would eliminate one method that is currently acceptable for assessing the realizability of DTAs related to AFS debt securities. That is, an entity would no longer be able to consider its intent and ability to hold debt securities with unrealized losses until recovery. 4. Disclosure of the fair value of financial instruments measured at amortized cost would no longer be required for entities that not public business entities. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. For all other entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Entities would be able to early adopt a provision that would allow them to recognize the fair value change from own credit in other comprehensive income for financial liabilities measured under the fair value option, and entities that are not public business entities would be able to adopt a provision to eliminate the fair value disclosures for financial instruments not recognized at fair value. Non-public business entities would be able to early adopt the guidance as of the effective date for public business entities. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. ASU 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”) In November 2015, the FASB issued ASU 2015-17, which require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments. For all other entities, the amendments are effective for financial statements issued for annual periods beginning after December 15, 2017, and interim periods within annual periods beginning after December 15, 2018. The Company is currently evaluating the impact of its pending adoption of ASU 2015-17 on its financial statements.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block]	On the declining balance method - Laboratory and office equipment 20% Computer equipment 30% On the straight-line method - Leasehold improvements over the lease term Manufacturing equipment 5 – 10 years

Leasehold Improvements and Eq25

Leasehold Improvements and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Leasehold Improvements and Equipment [Table Text Block]	2015 2014 Accumulated Net Carrying Net Carrying In U.S. $ thousands Cost Depreciation Amount Amount Manufacturing equipment $ 1,050 $ 0 $ 1,050 $ 520 Laboratory and office equipment 1,193 372 821 241 Computer equipment 64 47 17 15 Leasehold improvements 2,427 77 2,350 207 $ 4,734 $ 496 $ 4,238 $ 983

Long-term debt (Tables)

Long-term debt (Tables)	12 Months Ended
	Dec. 31, 2015
Term loan [Table Text Block]	December 31, 2015 December 31, 2014 In U.S.$ thousands $ $ Term loan facility 1,188 - Secured loan 542 - Total debt 1,730 - Less: current portion 184 - Total long-term debt 1,546 -
Term loan principal repayments [Table Text Block]	In U.S.$ thousands 2016 $184 2017 344 2018 344 2019 344 2020 344 Thereafter 170

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of future minimum payments under operating leases [Table Text Block]	In U.S.$ thousands 2016 $66 2017 81 2018 83 2019 84 2020 86 Thereafter 466

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Stock by Class [Table Text Block]	2015 2014 Authorized - 100,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 63,615,255 (December 31, 2014: 63,465,255) common shares $ 636 $ 635

Additional Paid-In Capital (Tab

Additional Paid-In Capital (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of 175,000 Stock Options Valuation - December 8, 2014 [Table Text Block]	Expected volatility 63% Expected life 3.13 years Risk-free interest rate 1.10% Dividend yield nil
Schedule of 200,000 Stock Options Valuation - April 2, 2015 [Table Text Block]	Expected volatility 66% Expected life 2.5 years Risk-free interest rate 0.87% Dividend yield nil
Schedule of 100,000 Stock Options Valuation - April 2, 2015 [Table Text Block]	Expected volatility 62% Expected life 3.13 years Risk-free interest rate 0.87% Dividend yield nil
Schedule of 600,000 Stock Options Valuation - July 20, 2015 [Table Text Block]	Expected volatility 63% Expected life 3.13 years Risk-free interest rate 1.09% Dividend yield nil
Schedule of 75,000 Stock Options Valuation - August 13, 2015 [Table Text Block]	Expected volatility 62% Expected life 3.13 years Risk-free interest rate 1.06% Dividend yield nil
Schedule of 150,000 Stock Options Valuation - December 14, 2015 [Table Text Block]	Expected volatility 63% Expected life 3.13 years Risk-free interest rate 1.25% Dividend yield nil
Schedule of Stock Option Activity to Employees and Directors[Table Text Block]	Weighted average Number of options exercise price $ Outstanding – January 1, 2014 1,597,500 0.58 Granted 175,000 0.53 Forfeited (517,500 ) (0.64 ) Expired (125,000 ) (0.61 ) Exercised - - Outstanding – December 31, 2014 1,130,000 0.54 Granted 1,125,000 0.58 Forfeited (410,000 ) (0.59 ) Expired (25,000 ) (0.45 ) Exercised (150,000 ) (0.41 ) Outstanding – December 31, 2015 1,670,000 0.56
Schedule of Stock Option Activity to Consultant's [Table Text Block]	Weighted average Number of options exercise price $ Outstanding – January 1, 2014 and 2015 100,000 0.59 Expired (100,000 ) 0.59 Outstanding – December 31, 2015 - -
Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block]	Outstanding options Exercisable options Weighted Weighted Weighted average average Aggregate average Aggregate Exercise Number of remaining exercise intrinsic Number of exercise intrinsic prices options contractual life price value options price value $ (years) $ $ $ $ 0.48 150,000 0.45 0.04 - - 0.51 20,000 0.02 0.01 20,000 0.01 0.52 50,000 0.01 0.02 50,000 0.04 0.52 150,000 0.27 0.05 150,000 0.11 0.53 150,000 0.36 0.05 75,000 0.06 0.54 110,000 0.06 0.04 110,000 0.09 0.58 35,000 0.06 0.01 35,000 0.03 0.58 600,000 1.65 0.21 - - 0.58 75,000 0.21 0.03 - - 0.60 30,000 0.04 0.01 30,000 0.03 0.62 300,000 0.76 0.11 225,000 0.20 1,670,000 3.88 0.56 6,200 695,000 0.56 200
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]	Number of Weighted average warrants exercise price (All Exercisable) $ Outstanding – January 1, 2014 11,143,732 0.6079 Exercised (2,480,988 ) (0.6524 ) Expired (1,431,621 ) (0.7400 ) Outstanding - December 31, 2014 7,231,123 0.5646 Exercised - - Expired - - Outstanding - December 31, 2015 7,231,123 0.5646

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	In U.S.$ thousands 2015 2014 Statutory income taxes $ 387 $ (429 ) Net operating losses for which no tax benefits have been recorded - 238 Net operating losses used for which no tax benefit had been recorded (484 ) - Excess (deficiency) of depreciation over capital cost allowance (98 ) 9 Non-deductible expenses 44 26 Undeducted research and development expenses 178 181 Investment tax credit (27 ) (25 ) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	In U.S.$ thousands 2015 2014 Leasehold improvements and equipment $ 117 $ 9 Net operating losses carryforward 1,770 2,582 Undeducted research and development expenses 1,274 1,355 Non-refundable tax credits carryforward 1,022 1,102 4,183 5,048 Valuation allowance (4,183 ) (5,048 ) $ - $ -

Statement of Cash Flows Infor31

Statement of Cash Flows Information (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	In US$ thousands 2015 2014 Additional Cash Flow Information: Interest paid $ 23 $ 5

Nature of Business (Narrative)

Nature of Business (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015
Nature Of Business 1	10

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)d
Summary Of Significant Accounting Policies 1 | d	45
Summary Of Significant Accounting Policies 2	$ 946,000
Summary Of Significant Accounting Policies 3	463,000
Summary Of Significant Accounting Policies 4	2,808,000
Summary Of Significant Accounting Policies 5	0
Summary Of Significant Accounting Policies 6	0
Summary Of Significant Accounting Policies 7	552
Summary Of Significant Accounting Policies 8	0
Summary Of Significant Accounting Policies 9	108,000
Summary Of Significant Accounting Policies 10	$ 268,000
Summary Of Significant Accounting Policies 11	50.00%

Leasehold Improvements and Eq34

Leasehold Improvements and Equipment (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Leasehold Improvements And Equipment 1	$ 471

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015
Intangible Assets 1	100.00%

Deferred License Revenue (Narra

Deferred License Revenue (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)mo
Deferred License Revenue 1 | mo	39
Deferred License Revenue 2	$ 1,250
Deferred License Revenue 3	$ 1,240

Bank indebtedness (Narrative) (

Bank indebtedness (Narrative) (Details) CAD in Thousands	12 Months Ended
	Dec. 31, 2015CAD
Bank Indebtedness 1	CAD 250
Bank Indebtedness 2	CAD 55
Bank Indebtedness 3	2.00%
Bank Indebtedness 4	50.00%

Long-term debt (Narrative) (Det

Long-term debt (Narrative) (Details) CAD in Thousands	12 Months Ended
	Dec. 31, 2015CADmo
Long-term Debt 1	CAD 3,500
Long-term Debt 2	CAD 1,600
Long-term Debt 3	2.50%
Long-term Debt 4	CAD 1,800
Long-term Debt 5	CAD 1,800
Long-term Debt 6 | mo	6
Long-term Debt 7 | mo	60
Long-term Debt 8	CAD 1,000
Long-term Debt 9	CAD 750
Long-term Debt 10	7.30%
Long-term Debt 11	CAD 125

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) - 12 months ended Dec. 31, 2015	USD ($)yr	CADyr
Commitments 1	17,000	17,000
Commitments 2 | yr	10	10
Commitments 3	6	6
Commitments 4 | CAD		CAD 110,000
Commitments 5	$ 80,000
Commitments 6 | CAD		CAD 0.25
Commitments 7	0.18
Commitments 8	866,000
Commitments 9	$ 200,000
Commitments 10	10.00%	10.00%
Commitments 11	$ 58,000
Commitments 12	$ 433

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)shares
Capital Stock 1 | shares	150,000
Capital Stock 2 | shares	150,000
Capital Stock 3	$ 0
Capital Stock 4	62,000
Capital Stock 5	62,000
Capital Stock 6	130,000
Capital Stock 7	101,000
Capital Stock 8	158,000
Capital Stock 9	$ 74,000
Capital Stock 10 | shares	2,480,988
Capital Stock 11 | shares	2,480,988
Capital Stock 12	$ 0
Capital Stock 13	1,619,000
Capital Stock 14	$ 1,619,000

Additional Paid-In Capital (Nar

Additional Paid-In Capital (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)yrmo$ / sharesshares
Additional Paid-in Capital 1 | shares	1,600,749
Additional Paid-in Capital 2	100.00%
Additional Paid-in Capital 3 | yr	10
Additional Paid-in Capital 4 | mo	24
Additional Paid-in Capital 5	100.00%
Additional Paid-in Capital 6 | yr	10
Additional Paid-in Capital 7 | yr	5
Additional Paid-in Capital 8	1,600,749
Additional Paid-in Capital 9	2,074,000
Additional Paid-in Capital 10	10.00%
Additional Paid-in Capital 11	3,308,127
Additional Paid-in Capital 12	5,030,292
Additional Paid-in Capital 13 | shares	175,000
Additional Paid-in Capital 14 | $ / shares	$ 0.53
Additional Paid-in Capital 15 | yr	2
Additional Paid-in Capital 16	25.00%
Additional Paid-in Capital 17	$ 36,000
Additional Paid-in Capital 18 | shares	200,000
Additional Paid-in Capital 19	$ 0.62
Additional Paid-in Capital 20	$ 45,000
Additional Paid-in Capital 21 | shares	100,000
Additional Paid-in Capital 22 | $ / shares	$ 0.62
Additional Paid-in Capital 23 | yr	2
Additional Paid-in Capital 24	25.00%
Additional Paid-in Capital 25	$ 24,000
Additional Paid-in Capital 26 | shares	600,000
Additional Paid-in Capital 27 | $ / shares	$ 0.58
Additional Paid-in Capital 28 | yr	2
Additional Paid-in Capital 29	25.00%
Additional Paid-in Capital 30	$ 120,000
Additional Paid-in Capital 31 | shares	75,000
Additional Paid-in Capital 32 | $ / shares	$ 0.58
Additional Paid-in Capital 33 | yr	2
Additional Paid-in Capital 34	25.00%
Additional Paid-in Capital 35	$ 15,000
Additional Paid-in Capital 36 | shares	150,000
Additional Paid-in Capital 37 | $ / shares	$ 0.48
Additional Paid-in Capital 38 | yr	2
Additional Paid-in Capital 39	25.00%
Additional Paid-in Capital 40	$ 25,000
Additional Paid-in Capital 41 | shares	150,000
Additional Paid-in Capital 42	150,000
Additional Paid-in Capital 43	$ 0
Additional Paid-in Capital 44	62,000
Additional Paid-in Capital 45	62,000
Additional Paid-in Capital 46	31,000
Additional Paid-in Capital 47	130,000
Additional Paid-in Capital 48	101,000
Additional Paid-in Capital 49	158,000
Additional Paid-in Capital 50	74,000
Additional Paid-in Capital 51	158,000
Additional Paid-in Capital 52	$ 158,000
Additional Paid-in Capital 53 | shares	2,480,988
Additional Paid-in Capital 54 | shares	2,480,988
Additional Paid-in Capital 55	$ 0
Additional Paid-in Capital 56	1,619,000
Additional Paid-in Capital 57	$ 1,619,000

Income Tax (Narrative) (Details

Income Tax (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Income Tax 1	$ 6,462
Income Tax 2	9,530
Income Tax 3	6,725
Income Tax 4	9,683
Income Tax 5	1,022
Income Tax 6	1,102
Income Tax 7	8
Income Tax 8	9
Income Tax 9	163
Income Tax 10	143
Income Tax 11	122
Income Tax 12	129
Income Tax 13	162
Income Tax 14	108
Income Tax 15	82
Income Tax 16	96
Income Tax 17	6,315
Income Tax 18	$ 4,805

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Related Party Transactions 1	$ 3,000
Related Party Transactions 2	29,000
Related Party Transactions 3	9,000
Related Party Transactions 4	0
Related Party Transactions 5	39,000
Related Party Transactions 6	43,000
Related Party Transactions 7	70,000
Related Party Transactions 8	17,000
Related Party Transactions 9	250,000
Related Party Transactions 10	$ 187,000

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details)	12 Months Ended
	Dec. 31, 2015yr
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 1	20.00%
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 2	30.00%
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 3	5
Summary Of Significant Accounting Policies Schedule Of Leasehold Improvements And Equipment 4	10

Schedule of Leasehold Improveme

Schedule of Leasehold Improvements and Equipment (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 1	$ 1,050
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 2	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 3	1,050
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 4	520
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 5	1,193
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 6	372
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 7	821
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 8	241
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 9	64
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 10	47
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 11	17
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 12	15
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 13	2,427
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 14	77
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 15	2,350
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 16	207
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 17	4,734
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 18	496
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 19	4,238
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 20	$ 983

Term loan (Details)

Term loan (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Long-term Debt Term Loan 1	$ 1,188
Long-term Debt Term Loan 2	0
Long-term Debt Term Loan 3	542
Long-term Debt Term Loan 4	0
Long-term Debt Term Loan 5	1,730
Long-term Debt Term Loan 6	0
Long-term Debt Term Loan 7	184
Long-term Debt Term Loan 8	0
Long-term Debt Term Loan 9	1,546
Long-term Debt Term Loan 10	$ 0

Term loan principal repayments

Term loan principal repayments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Long-term Debt Term Loan Principal Repayments 1	$ 184
Long-term Debt Term Loan Principal Repayments 2	344
Long-term Debt Term Loan Principal Repayments 3	344
Long-term Debt Term Loan Principal Repayments 4	344
Long-term Debt Term Loan Principal Repayments 5	344
Long-term Debt Term Loan Principal Repayments 6	$ 170

Schedule of future minimum paym

Schedule of future minimum payments under operating leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Commitments Schedule Of Future Minimum Payments Under Operating Leases 1	$ 66
Commitments Schedule Of Future Minimum Payments Under Operating Leases 2	81
Commitments Schedule Of Future Minimum Payments Under Operating Leases 3	83
Commitments Schedule Of Future Minimum Payments Under Operating Leases 4	84
Commitments Schedule Of Future Minimum Payments Under Operating Leases 5	86
Commitments Schedule Of Future Minimum Payments Under Operating Leases 6	$ 466

Schedule of Stock by Class (Det

Schedule of Stock by Class (Details)	12 Months Ended
	Dec. 31, 2015USD ($)shares
Capital Stock Schedule Of Stock By Class 1 | shares	100,000,000
Capital Stock Schedule Of Stock By Class 2	$ 0.00001
Capital Stock Schedule Of Stock By Class 3 | shares	20,000,000
Capital Stock Schedule Of Stock By Class 4	$ 0.00001
Capital Stock Schedule Of Stock By Class 5	$ 63,615,255
Capital Stock Schedule Of Stock By Class 6 | shares	63,465,255
Capital Stock Schedule Of Stock By Class 7	$ 636
Capital Stock Schedule Of Stock By Class 8	$ 635

Schedule of 175,000 Stock Optio

Schedule of 175,000 Stock Options Valuation - December 8, 2014 (Details)	12 Months Ended
	Dec. 31, 2015USD ($)yr
Additional Paid-in Capital Schedule Of 175,000 Stock Options Valuation - December 8, 2014 1	63.00%
Additional Paid-in Capital Schedule Of 175,000 Stock Options Valuation - December 8, 2014 2 | yr	3.13
Additional Paid-in Capital Schedule Of 175,000 Stock Options Valuation - December 8, 2014 3	1.10%
Additional Paid-in Capital Schedule Of 175,000 Stock Options Valuation - December 8, 2014 4 | $	$ 0

Schedule of 200,000 Stock Optio

Schedule of 200,000 Stock Options Valuation - April 2, 2015 (Details)	12 Months Ended
	Dec. 31, 2015USD ($)yr
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 2, 2015 1	66.00%
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 2, 2015 2 | yr	2.5
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 2, 2015 3	0.87%
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 2, 2015 4 | $	$ 0

Schedule of 100,000 Stock Optio

Schedule of 100,000 Stock Options Valuation - April 2, 2015 (Details)	12 Months Ended
	Dec. 31, 2015USD ($)yr
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - April 2, 2015 1	62.00%
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - April 2, 2015 2 | yr	3.13
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - April 2, 2015 3	0.87%
Additional Paid-in Capital Schedule Of 100,000 Stock Options Valuation - April 2, 2015 4 | $	$ 0

Schedule of 600,000 Stock Optio

Schedule of 600,000 Stock Options Valuation - July 20, 2015 (Details)	12 Months Ended
	Dec. 31, 2015USD ($)yr
Additional Paid-in Capital Schedule Of 600,000 Stock Options Valuation - July 20, 2015 1	63.00%
Additional Paid-in Capital Schedule Of 600,000 Stock Options Valuation - July 20, 2015 2 | yr	3.13
Additional Paid-in Capital Schedule Of 600,000 Stock Options Valuation - July 20, 2015 3	1.09%
Additional Paid-in Capital Schedule Of 600,000 Stock Options Valuation - July 20, 2015 4 | $	$ 0

Schedule of 75,000 Stock Option

Schedule of 75,000 Stock Options Valuation - August 13, 2015 (Details)	12 Months Ended
	Dec. 31, 2015USD ($)yr
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - August 13, 2015 1	62.00%
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - August 13, 2015 2 | yr	3.13
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - August 13, 2015 3	1.06%
Additional Paid-in Capital Schedule Of 75,000 Stock Options Valuation - August 13, 2015 4 | $	$ 0

Schedule of 150,000 Stock Optio

Schedule of 150,000 Stock Options Valuation - December 14, 2015 (Details)	12 Months Ended
	Dec. 31, 2015USD ($)yr
Additional Paid-in Capital Schedule Of 150,000 Stock Options Valuation - December 14, 2015 1	63.00%
Additional Paid-in Capital Schedule Of 150,000 Stock Options Valuation - December 14, 2015 2 | yr	3.13
Additional Paid-in Capital Schedule Of 150,000 Stock Options Valuation - December 14, 2015 3	1.25%
Additional Paid-in Capital Schedule Of 150,000 Stock Options Valuation - December 14, 2015 4 | $	$ 0

Schedule of Stock Option Activi

Schedule of Stock Option Activity to Employees and Directors[Table Text Block] (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 1	$ 1,597,500
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 2	0.58
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 3	$ 175,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 4	0.53
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 5	$ (517,500)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 6	(0.64)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 7	$ (125,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 8	(0.61)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 9	$ 0
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 10	0
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 11	$ 1,130,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 12	0.54
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 13	$ 1,125,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 14	0.58
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 15	$ (410,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 16	(0.59)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 17	$ (25,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 18	(0.45)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 19	$ (150,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 20	(0.41)
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 21	$ 1,670,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Employees And Director 22	0.56

Schedule of Stock Option Acti57

Schedule of Stock Option Activity to Consultant's (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 1	$ 100,000
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 2	0.59
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 3	$ (100,000)
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 4	0.59
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 5	$ 0
Additional Paid-in Capital Schedule Of Stock Option Activity To Consultant's 6	$ 0

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1	0.48
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2	$ 150,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3	0.45
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5	$ 0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6	$ 0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 7	0.51
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 8	$ 20,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 9	0.02
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 10	0.01
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 11	$ 20,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 12	0.01
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 13	0.52
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 14	$ 50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 15	0.01
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 16	0.02
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 17	$ 50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 18	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 19	0.52
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 20	$ 150,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 21	0.27
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 22	0.05
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 23	$ 150,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 24	0.11
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 25	0.53
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 26	$ 150,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 27	0.36
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 28	0.05
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 29	$ 75,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 30	0.06
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 31	0.54
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 32	$ 110,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 33	0.06
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 34	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 35	$ 110,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 36	0.09
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 37	0.58
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 38	$ 35,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 39	0.06
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 40	0.01
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 41	$ 35,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 42	0.03
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 43	0.58
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 44	$ 600,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 45	1.65
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 46	0.21
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 47	$ 0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 48	$ 0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 49	0.58
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 50	$ 75,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 51	0.21
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 52	0.03
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 53	$ 0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 54	$ 0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 55	0.60
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 56	$ 30,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 57	0.04
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 58	0.01
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 59	$ 30,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 60	0.03
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 61	0.62
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 62	$ 300,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 63	0.76
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 64	0.11
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 65	$ 225,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 66	0.20
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 67	$ 1,670,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 68	3.88
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 69	0.56
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 70	$ 6,200
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 71	$ 695,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 72	0.56
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 73	$ 200

Schedule of Stockholders' Equit

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1	$ 11,143,732
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2	0.6079
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3	$ (2,480,988)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4	(0.6524)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5	$ (1,431,621)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6	(0.7400)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7	$ 7,231,123
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8	0.5646
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9	$ 0
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10	0
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11	0
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12	0
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13	$ 7,231,123
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14	0.5646

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 1	$ 387
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 2	(429)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 3	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 4	238
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 5	(484)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 6	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 7	(98)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 8	9
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 9	44
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 10	26
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 11	178
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 12	181
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 13	(27)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 14	(25)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 15	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 16	$ 0

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Income Tax Schedule Of Deferred Tax Assets And Liabilities 1	$ 117
Income Tax Schedule Of Deferred Tax Assets And Liabilities 2	9
Income Tax Schedule Of Deferred Tax Assets And Liabilities 3	1,770
Income Tax Schedule Of Deferred Tax Assets And Liabilities 4	2,582
Income Tax Schedule Of Deferred Tax Assets And Liabilities 5	1,274
Income Tax Schedule Of Deferred Tax Assets And Liabilities 6	1,355
Income Tax Schedule Of Deferred Tax Assets And Liabilities 7	1,022
Income Tax Schedule Of Deferred Tax Assets And Liabilities 8	1,102
Income Tax Schedule Of Deferred Tax Assets And Liabilities 9	4,183
Income Tax Schedule Of Deferred Tax Assets And Liabilities 10	5,048
Income Tax Schedule Of Deferred Tax Assets And Liabilities 11	(4,183)
Income Tax Schedule Of Deferred Tax Assets And Liabilities 12	(5,048)
Income Tax Schedule Of Deferred Tax Assets And Liabilities 13	0
Income Tax Schedule Of Deferred Tax Assets And Liabilities 14	$ 0

Schedule of Cash Flow, Suppleme

Schedule of Cash Flow, Supplemental Disclosures (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 1	$ 23
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 2	$ 5